Prostatic adenocarcinoma metastatic to the breasts: report of a case with diagnosis by fine needle aspiration biopsy

Yan, Zi; Hummel, Pascale; Waisman, Jerry; Newstead, Gillian M.; Chachoua, Abraham; Chhieng, David C.; Cohen, Jean‐Marc; Cangiarella, Joan

doi:10.1016/s0090-4295(99)00560-9

Cited by 6 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metastatic malignancies involving the breast are associated with a poor prognosis, with the majority of patients dying within one year of diagnosis[7-9]. Treatment generally involves systemic chemotherapy, and correct diagnosis is essential to provide accurate prognostic information and prevent unnecessary surgery in these patients.…”

Section: Introductionmentioning

confidence: 99%

Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma

2010

View full text Add to dashboard Cite

BackgroundProstate carcinoma is among the most common solid tumors to secondarily involve the male breast. Prostate specific antigen (PSA) and prostate-specific acid phosphatase (PSAP) are expressed in benign and malignant prostatic tissue, and immunohistochemical staining for these markers is often used to confirm the prostatic origin of metastatic carcinoma. PSA expression has been reported in male and female breast carcinoma and in gynecomastia, raising concerns about the utility of PSA for differentiating prostate carcinoma metastasis to the male breast from primary breast carcinoma. This study examined the frequency of PSA, PSAP, and hormone receptor expression in male breast carcinoma (MBC), female breast carcinoma (FBC), and gynecomastia.MethodsImmunohistochemical staining for PSA, PSAP, AR, ER, and PR was performed on tissue microarrays representing six cases of gynecomastia, thirty MBC, and fifty-six FBC.ResultsPSA was positive in two of fifty-six FBC (3.7%), focally positive in one of thirty MBC (3.3%), and negative in the five examined cases of gynecomastia. PSAP expression was absent in MBC, FBC, and gynecomastia. Hormone receptor expression was similar in males and females (AR 74.1% in MBC vs. 67.9% in FBC, p = 0.62; ER 85.2% vs. 68.5%, p = 0.18; and PR 51.9% vs. 48.2%, p = 0.82).ConclusionsPSA and PSAP are useful markers to distinguish primary breast carcinoma from prostate carcinoma metastatic to the male breast. Although PSA expression appeared to correlate with hormone receptor expression, the incidence of PSA expression in our population was too low to draw significant conclusions about an association between PSA expression and hormone receptor status in breast lesions.

show abstract

Section: Introductionmentioning

confidence: 99%

Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma

2010

View full text Add to dashboard Cite

show abstract

“…[1][2][3] Metastatic adenocarcinoma, in particular those of prostatic origin, may have dramatic overlap in cytomorphology with primary breast carcinoma, in that both demonstrate cribriform or acinar architecture, cohesive homogeneous cells, and prominent nucleoli. Therefore, the cytological diagnosis of metastatic prostate carcinoma may be difficult, particularly in cases with a unilateral mass and/or an unknown clinical history.…”

Section: Dear Dr Bedrossianmentioning

confidence: 99%

Fine‐needle aspiration biopsy diagnosis of prostate carcinoma metastatic to the breast

Navolotskaia

Cai

2009

Diagnostic Cytopathology

View full text Add to dashboard Cite

“…4,[8][9][10] In Korea, there have been a few cases of breast metastases from extramammary sites. [11][12][13][14][15][16][17][18] We retrospectively reviewed the surgical archives of Asan Medical Center to identify the patients who had histopathologically and clinically confirmed extramammary metastases to the breast and to analyze their clinicopathologic characteristics. To date, this is the largest series of metastatic lesions of the breast from extramammary malignancies to be described in Korea.…”

mentioning

confidence: 99%

Metastatic Tumors to the Breast from Extramammary Malignancies

et al. 2010

View full text Add to dashboard Cite

Background : Metastases to the breast from extramammary malignancies are very rare. We describe here the clinicopathologic features of the metastatic breast tumors that were identified in Korean patients at a single institute. Methods : We analyzed the clinicopathologic data of the patients who were diagnosed between January 1989 and April 2009 at Asan Medical Center. Results : Only 31 (0.21%) patients with metastases to the breast from extramammary malignancies were diagnosed over a 20-year period, and 29 of them had available data. The mean time to the diagnosis of metastasis after the diagnosis of the primary malignancy was 21 months (range, 0 to 102 months). The most common primary site was the stomach, followed by the uterus and lung. The most common histologic type was adenocarcinoma. A common clinical presentation was a unilateral palpable mass. Most metastatic tumors had morphological features that were similar to those of their respective primary tumors. However, in situ carcinoma, microcalcification and desmoplastic reactions were rarely observed. Conclusions : Metastatic breast lesions from extramammary sites are extremely rare, and the stomach, uterus and lung could be considered as the common primary sites in Korean patients. The clinical history and comparing the morphology of the primary tumor with the morphology of the metastatic tumor are important for achieving the proper diagnosis.

show abstract

Prostatic adenocarcinoma metastatic to the breasts: report of a case with diagnosis by fine needle aspiration biopsy

Cited by 6 publications

References 12 publications

Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma

Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma

Fine‐needle aspiration biopsy diagnosis of prostate carcinoma metastatic to the breast

Metastatic Tumors to the Breast from Extramammary Malignancies

Contact Info

Product

Resources

About